Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial - Top-Institutions - MDSpire

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • By

  • Jinhong Zhu

  • Jinfeng Zhang

  • Xiaodong Ling

  • Changhong Wang

  • Yingnan Yang

  • Yangzhong Xin

  • Hao Jiang

  • Hao Liang

  • Luquan Zhang

  • Xionghai Qin

  • Jingle Lei

  • Chengyuan Fang

  • Xinxin Yang

  • Yuning Wang

  • Wei Meng

  • Xiaoyuan Wang

  • Hongxue Meng

  • Jianqun Ma

  • December 28, 2025

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Chinese Academy of Medical Sciences Cancer Hospital (National Cancer Center)
    Chinese Academy of Medical Sciences Cancer Hospital (National Cancer Center)

    Beijing, Beijing

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Radiation Oncology
    • Translational Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Radiation Oncology
    • Immunotherapy Research

  • #3

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Radiation Oncology
    • Clinical Trials

  • #4

    National Cancer Center Hospital East
    National Cancer Center Hospital East

    Kashiwa, Chiba

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Radiation Oncology

  • #5

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, Shanghai

    Key Differentiators

    • Medical Oncology
    • Surgical Oncology
    • Translational Research

Original Source(s)

Preoperative Combination Therapy with Camrelizumab, Paclitaxel, and Nedaplatin for Unresectable Advanced Esophageal Squamous Cell Carcinoma: Results from a Phase 2 Trial

  • by Jinhong Zhu, Jinfeng Zhang, Xiaodong Ling, Changhong Wang, Yingnan Yang, Yangzhong Xin, Hao Jiang, Hao Liang, Luquan Zhang, Xionghai Qin, Jingle Lei, Chengyuan Fang, Xinxin Yang, Yuning Wang, Wei Meng, Xiaoyuan Wang, Hongxue Meng, Jianqun Ma

  • December 28, 2025

Related Content

Long-term Effects and Anorectal Function in Patients with Anal Squamous Cell Carcinoma Following Intensity-Modulated Radiotherapy

Successful management of metachronous dual primary esophageal carcinomas: first report of consecutive adenoid cystic carcinoma and squamous cell carcinoma with exceptional treatment outcome—a case report

From Sophie Spitz to Molecular Melanocytoma

How one woman's pioneering research transformed pediatric melanoma diagnosis